title: Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease.
abstract: OBJECTIVE
  We evaluated the risk of death from Alzheimer disease (AD) in men with prostate cancer undergoing treatment with or without a luteinizing-hormone releasing hormone (LHRH) agonist.
  
  
  METHODS
  Between 1997 and 2007, 6,647 men were treated with brachytherapy for prostate cancer with (N = 1,700) or without (N = 4,947) LHRH agonist therapy. Competing risks multivariable regression was performed to assess whether the use of a LHRH agonist was associated with the risk of death from AD adjusting for the presence of mild AD and age at presentation and known prostate cancer prognostic factors.
  
  
  RESULTS
  After a median follow-up of 4.1 years, 1.2% (81/6,647) of the study cohort died from AD accounting for 16% (81/506) of all observed mortality. There was a significant reduction in the risk of death from AD in men who were treated with a LHRH agonist for a median of 4.0 months as compared with those who were not [adjusted hazard ratio: 0.45 (95% confidence interval, 0.25-0.83); P = 0.01].
  
  
  CONCLUSIONS
  LHRH agonist use as compared with no use in men with prostate cancer was associated with a decreased risk of death from AD.
authors.affiliation: Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute, Boston, MA, USA. adamico@partners.org
authors.forename: Anthony V
authors.initials: AV
authors.lastname: D'Amico
authors.forename: Michelle H
authors.initials: MH
authors.lastname: Braccioforte
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Moran
authors.forename: Ming-Hui
authors.initials: MH
authors.lastname: Chen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000097:blood / Q000150:complications / Q000401:mortality*; D015415:Biomarkers / Q000097:blood; D001918:Brachytherapy; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011471:Prostatic Neoplasms / Q000097:blood / Q000150:complications / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D015415:Biomarkers; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone